Evercore ISI views the 10% selloff today in shares of Gilead after Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer as an overreaction. The reason to like the shares is that Gilead is a long-term growth story, and that remains fully intact, the analyst tells investors in a research note. The firm had viewed EVOKE-01 as a high risk study and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GILD:
- Gilead (NASDAQ:GILD) Tumbles after Setback in Phase 3 Lung Cancer Study
- Day One Biopharmaceuticals announces two new appointments to board
- Arcus Biosciences announces ‘promising’ ARC-8 Phase 1b study data
- The biopharmaceuticals stocks to own in 2024, according to BofA
- Gilead stock could finally have breakout year, Barron’s says